Patents Assigned to TOPIVERT PHARMA LIMITED
-
Patent number: 10882859Abstract: There are provided compounds of formula I, wherein X, Ak, s, A, R1 and R2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: December 11, 2019Date of Patent: January 5, 2021Assignee: TOPIVERT PHARMA LIMITEDInventor: Matthew Colin Thor Fyfe
-
Patent number: 10851097Abstract: There are provided compounds of formula (I), wherein X, Ak, s, L, Q, R1 and R2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: November 2, 2016Date of Patent: December 1, 2020Assignee: TOPIVERT PHARMA LIMITEDInventor: Matthew Colin Thor Fyfe
-
Patent number: 10556901Abstract: There are provided compounds of formula I, wherein X, Ak, s, A, R1 and R2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: November 2, 2016Date of Patent: February 11, 2020Assignee: Topivert Pharma LimitedInventor: Matthew Colin Thor Fyfe
-
Patent number: 10442828Abstract: There are provided compounds of: wherein T, A, Q, Z, R4, R5a, R5b, n, r, Het1 and Rx have meanings given in the description, which compounds are useful in synthesizing compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: June 28, 2018Date of Patent: October 15, 2019Assignee: Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom
-
Patent number: 10435361Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 5, 2017Date of Patent: October 8, 2019Assignee: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Gareth William Harbottle, Vedran Hasimbegovic, Premji Meghani, Aaron Rigby, Colin Sambrook-Smith, Stephen Malcolm Thom
-
Patent number: 10392346Abstract: There are provided compounds of formula IIb, wherein: LG1 represents imidazolyl, chloro, or aryloxy; and Z1 represents a structural fragment of formula V: wherein R2 to R4, R5a, L and X1 to X3 have meanings given in the description, or a salt or protected derivative thereof, wherein said protected derivative is a compound in which the carboxyl moiety of R4 is protected as a C1-8 alkyl ester. The compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 13, 2018Date of Patent: August 27, 2019Assignee: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Patent number: 10301288Abstract: There are provided compounds of formula (III), or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula (V), wherein R1, Ra, Rb, X and Y have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: December 4, 2017Date of Patent: May 28, 2019Assignee: Topivert Pharma LimitedInventor: Matthew Colin Thor Fyfe
-
Patent number: 10125100Abstract: There are provided compounds of formulas III and VIIa: or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula V, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: May 24, 2017Date of Patent: November 13, 2018Assignees: Topivert Pharma LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Patent number: 10072034Abstract: There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: April 6, 2017Date of Patent: September 11, 2018Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom
-
Patent number: 9890185Abstract: There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: December 19, 2014Date of Patent: February 13, 2018Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Stephen Malcolm Thom, Thomas Matthew Baker, Gareth William Harbottle, Vedran Hasimbegovic, Aaron Rigby
-
Patent number: 9850233Abstract: There are provided compounds of formula I, wherein: Y represents NR2R3; one of R2 and R3 represents —[C2-4 alkylene-O]1-12—[C2-4 alkylene]-R2a and the other of R2 and R3 has a meaning given in the description; and R, R1, R2a, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 12, 2016Date of Patent: December 26, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventor: Matthew Colin Thor Fyfe
-
Patent number: 9822076Abstract: There is provided a compound of formula VIIa, wherein Qx represents —C(O)O—C1-4 alkyl, or a salt or protected derivative thereof, and other compounds that are useful in the preparation of compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 12, 2016Date of Patent: November 21, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventor: Matthew Colin Thor Fyfe
-
Patent number: 9796742Abstract: There are provided compounds of formula I, wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 4, 2016Date of Patent: October 24, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Michael Knaggs, Premji Meghani, Stephen Malcolm Thom
-
Patent number: 9790209Abstract: There are provided compounds of formula I, wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 1, 2016Date of Patent: October 17, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Premji Meghani, Matthew Alexander Henry Stent, Stephen Malcolm Thom, Claire Anne Walshe
-
Patent number: 9790174Abstract: There are provided compounds of formula IIb, wherein LG1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: September 9, 2016Date of Patent: October 17, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventor: Stephen Malcolm Thom
-
Patent number: 9783556Abstract: There are provided compounds of formula I, (I): wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 28, 2013Date of Patent: October 10, 2017Assignees: Respivert Limited, Topivert Pharma LimitedInventors: Matthew Colin Thor Fyfe, Premji Meghani, Stephen Malcolm Thom
-
Patent number: 9771353Abstract: Compounds are of formula (I): The compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: April 1, 2014Date of Patent: September 26, 2017Assignees: TOPIVERT PHARMA LIMITED, RESPIVERT LIMITEDInventor: Matthew Colin Thor Fyfe
-
Patent number: 9751837Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: October 1, 2015Date of Patent: September 5, 2017Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom
-
Patent number: 9732063Abstract: In compounds of formula I: R1 to R5, Ar and X1 to X3 have defined meanings. The compounds have anti-inflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: November 15, 2013Date of Patent: August 15, 2017Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Fritz-Frieder Frickel, Matthew Colin Thor Fyfe, Premji Meghani, Stephen Malcolm Thom
-
Patent number: 9701670Abstract: There are provided compounds of formula I, wherein R, R1, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: August 16, 2013Date of Patent: July 11, 2017Assignees: RESPIVERT LIMITED, TOPIVERT PHARMA LIMITEDInventors: Claire Anne Marie Cariou, Catherine Elisabeth Charron, Euan Alexander Fraser Fordyce, Daniel Hamza, Matthew Colin Thor Fyfe, Kazuhiro Ito, John King-Underwood, Peter John Murray, Stuart Thomas Onions, Stephen Malcolm Thom, Hayley Tegan Angela Watson, Jonathan Gareth Williams